The four Janus kinase (JAK) proteins and seven signal transducer and activator of
transcription (STAT) transcription factors mediate intracellular signal transduction …

Janus kinase (JAK) is a family of cytoplasmic non-receptor tyrosine kinases that includes
four members, namely JAK1, JAK2, JAK3, and TYK2. The JAKs transduce cytokine signaling …

Background Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of
psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate …

Objectives Janus kinase inhibitors (JAKi) have been approved for use in various immune-
mediated inflammatory diseases. With five agents licensed, it was timely to summarise the …

Objective To update the European League Against Rheumatism (EULAR) recommendations
for the pharmacological treatment of psoriatic arthritis (PsA). Methods According to the …

Objective To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing
spondylitis (AS). Methods This phase III, randomised, double-blind, placebo-controlled study …

Small molecule JAK inhibitors have emerged as a major therapeutic advancement in
treating autoimmune diseases. The discovery of isoform selective JAK inhibitors that …

Janus kinase (JAK)/signal transducers and activators of transcription (STATs) are a group of
molecules associated with one of the major pathways through which many cytokines exert …

Accumulating data on cellular and molecular pathways help to develop novel therapeutic
strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic …

Cytokines play a central role in the pathophysiology of autoimmune and inflammatory
diseases. Several cytokines signal through the JAK-STAT pathway, which is now recognized …